An MDS xenograft model utilizing a patient-derived cell line

Leukemia

Volumn 28, Issue 5, 2014, Pages 1142-1145

  Rhyasen, G W ^a,b   Wunderlich, M ^a   Tohyama, K ^c   Garcia Manero, G ^d   Mulloy, J C ^a   Starczynowski, D T ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW CELL; CANCER TRANSPLANTATION; CELL STRUCTURE; CELL TRANSPLANTATION; DRUG EFFICACY; DRUG SCREENING; ENGRAFTMENT; GRAFT RECIPIENT; HUMAN; HUMAN CELL; LETTER; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; STROMA CELL; XENOGRAFT;

ANIMALS; CELL LINE; HETEROGRAFTS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 84899988429     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.372     Document Type: Letter

References (15)

1. Nilsson L A-GI, Anderson K, Arvidsson I, Hokland P, Bryder D, Kjeldsen L. et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002; 100: 259-267.
2. Nilsson L A-GI, Arvidsson I, Jacobsson B, Hellstrom-Lindberg E, Hast R. et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5qdeleted myelodysplastic syndromes: Evidence for involvement at the hematopoietic stem cell level. Blood 2000; 96: 2012-2021.
3. Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 2004; 103: 4285-4293.
4. Benito AI, Bryant E, Loken MR, Sale GE, Nash RA, John Gass M. et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-Term propagation of normal but not clonal human precursors. Leuk Res 2003; 27: 425-436.
5. Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL. et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci USA 2013; 110: 3011-3016.
6. Kerbauy DM, Lesnikov V, Torok-Storb B, Bryant E, Deeg HJ. Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2- microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells. Blood 2004; 104: 2202-2203.
7. Tohyama KTH, Ueda T, Nakamura T, Yoshida Y. Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Brit J Haematol 1994; 87: 235-242.
8. Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T. et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia 2010; 24: 748-755.
9. Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C. et al. Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. Cancer cell 2013; 24: 90-104.
10. Tohyama K. Human factor-dependent leukemia cell lines. Int J Hematol 1997; 65: 309-317.
11. Tohyama K TY, Nakayama T, Ueda T, Nakamura T, Yoshida Y. A novel factordependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages. Br J Haematol 1995; 91: 795-799.
12. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M. et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 2010; 24: 1785-1788.
13. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765-3776.
14. Marisavljevic Dea. Hypocellular myelodysplastic syndromes: Clinical and biological significance. Med Oncol 2005; 22: 169-175.
15. Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y. et al. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood 2013; 121: E90-e97.